Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity

• Published in: The FASEB journal Vol. 37; no. 11; p. e23220
• Main Authors: Tedbury, Philip R, Manfredi, Candela, Degenhardt, Frauke, Conway, Joseph, Horwath, Michael C, McCracken, Courtney, Sorscher, Adam J, Moreau, Sandy, Wright, Christine, Edwards, Carolina, Brewer, Jo, Guarner, Jeannette, de Wit, Emmie, Williamson, Brandi N, Suthar, Mehul S, Ong, Yee T, Roback, John D, Alter, David N, Holter, Jan C, Karlsen, Tom H, Sacchi, Nicoletta, Romero-Gómez, Manuel, Invernizzi, Pietro, Fernández, Javier, Buti, Maria, Albillos, Agustin, Julià, Antonio, Valenti, Luca, Asselta, Rosanna, Banales, Jesus M, Bujanda, Luis, de Cid, Rafael, Franke, André, Sarafianos, Stefan G, Hong, Jeong S, Sorscher, Eric J, Ehrhardt, Annette
• Format: Journal Article
• Language: English
• Published: United States 01.11.2023
• Subjects: COVID-19; Cystic Fibrosis - complications; Cystic Fibrosis - genetics; Cystic Fibrosis Transmembrane Conductance Regulator - genetics; Humans; Mutation; Patient Acuity; SARS-CoV-2; COVID-19; cystic fibrosis transmembrane conductance regulator; SARS-CoV-2; comorbidity; virus replication; mucus membrane
• ISSN: 1530-6860
• DOI: 10.1096/fj.202300077R

Patients with cystic fibrosis (CF) exhibit pronounced respiratory damage and were initially considered among those at highest risk for serious harm from SARS-CoV-2 infection. Numerous clinical studies have subsequently reported that individuals with CF in North America and Europe-while susceptible t...